"Sept. 1, 2011 -- The FDA warns that the osteoporosis drug Reclast (zoledronic acid) raises the risk of kidney failure.
The warning is targeted at patients who already suffer from kidney impairment. It's also aimed at those who are tak"...
Clinical experience with acute overdosage of zoledronic acid (Reclast) solution for intravenous infusion is limited. Patients who have received doses higher than those recommended should be carefully monitored. Overdosage may cause clinically significant renal impairment, hypocalcemia, hypophosphatemia, and hypomagnesemia. Clinically relevant reductions in serum levels of calcium, phosphorus, and magnesium should be corrected by intravenous administration of calcium gluconate, potassium or sodium phosphate, and magnesium sulfate, respectively.
Single doses of Reclast should not exceed 5 mg and the duration of the intravenous infusion should be no less than 15 minutes [see DOSAGE AND ADMINISTRATION].
Reclast is contraindicated in patients with the following conditions:
- Hypocalcemia [see WARNINGS AND PRECAUTIONS]
- Creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see WARNINGS AND PRECAUTIONS].
- Known hypersensitivity to zoledronic acid or any components of Reclast. Hypersensitivity reactions including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see Post-Marketing Experienc].
Last reviewed on RxList: 4/25/2016
Additional Reclast Information
Reclast - User Reviews
Reclast User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips and advances in treatment.